Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AIM ImmunoTech Inc (AIM)
NYSE MKT:AIM
Holding AIM?
Track your performance easily
AIM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.21 - $0.62
Previous Close$0.24
Volume222.43K
Average Volume (3M)290.95K
Market Cap
$15.58M
Enterprise Value$8.88M
Total Cash (Recent Filing)$10.06M
Total Debt (Recent Filing)$3.36M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 15, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding57,136,680
10 Day Avg. Volume205,057
30 Day Avg. Volume290,947
Standard Deviation0.26
R-Squared0.00543
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.22
Price to Sales (P/S)69.53
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue47.49
Enterprise Value/Gross Profit55.50
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$3.00Price Target Upside1129.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
AIM ImmunoTech News
PremiumCompany Announcements
AIM ImmunoTech Adjusts Executive Compensation and Agreements
Ownership Overview
3.41% Insiders
3.79% Mutual Funds
0.09% Other Institutional Investors
89.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AIM FAQ
What was AIM ImmunoTech Inc’s price range in the past 12 months?
AIM ImmunoTech Inc lowest stock price was $0.21 and its highest was $0.62 in the past 12 months.
What is AIM ImmunoTech Inc’s market cap?
Currently, no data Available
When is AIM ImmunoTech Inc’s upcoming earnings report date?
AIM ImmunoTech Inc’s upcoming earnings report date is Nov 15, 2024 which is in 5 days.
How were AIM ImmunoTech Inc’s earnings last quarter?
AIM ImmunoTech Inc released its earnings results on Aug 16, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.093.
Is AIM ImmunoTech Inc overvalued?
According to Wall Street analysts AIM ImmunoTech Inc’s price is currently Undervalued.
Does AIM ImmunoTech Inc pay dividends?
AIM ImmunoTech Inc does not currently pay dividends.
What is AIM ImmunoTech Inc’s EPS estimate?
AIM ImmunoTech Inc’s EPS estimate is -$0.09.
How many shares outstanding does AIM ImmunoTech Inc have?
AIM ImmunoTech Inc has 63,706,448 shares outstanding.
What happened to AIM ImmunoTech Inc’s price movement after its last earnings report?
AIM ImmunoTech Inc reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of AIM ImmunoTech Inc?
Currently, no hedge funds are holding shares in AIM
---
AIM ImmunoTech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (1129.51% Upside)
$3.00 (1129.51% Upside)
Insider Transactions
Bought Shares
Worth $7.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.86%
12-Months-Change
Fundamentals
Return on Equity
-154.79%
Trailing 12-Months
Asset Growth
-53.25%
Trailing 12-Months
Company Description
AIM ImmunoTech Inc
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
---
AIM Earnings Call
Q2 2024
0:00 / 0:00
---
AIM Stock 12 Month Forecast
Average Price Target
$3.00
▲(1129.51% Upside)
Technical Analysis
Best Analysts Covering AIM
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-25.85%
reiterated a buy rating 20 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -25.85% per trade.
---